Kexing Biopharm Expands Global Reach at CPHI Milan Event

Kexing Biopharm (688136.SH) participated in CPHI Milan 2026 from October 6-8, 2026, presenting its global pipeline of innovative drugs and co-developed biosimilars. The company engaged with pharmaceutical buyers, biotech firms, and industry partners worldwide, aiming to foster international cooperation.

In recent years, Kexing Biopharm has built an established international marketing platform, securing cooperation agreements for over 30 products with multiple global pharmaceutical companies. Its marketing network covers approximately 70 countries and regions, with nearly 200 overseas registration applications filed.

Europe is a key market for Kexing Biopharm, particularly for its flagship product, albumin-bound paclitaxel, which is already marketed in the EU and the UK. The company is also developing more than 10 high-value biosimilars for global markets, targeting unmet clinical needs.

To bolster its local presence in Europe, Kexing Biopharm has established a subsidiary in Germany and plans to set up operations in France, Spain, Italy, the UK, and the Netherlands. This local approach aims to more effectively meet customer needs and build lasting partnerships.

The company's strategic focus is "Innovation + Internationalization." Innovative drug projects presented at the event included advancements in areas such as cancer cachexia, ophthalmic drugs, lupus, and inflammatory bowel disease. Kexing Biopharm highlighted its 30 years of industrial experience and its EU GMP-certified manufacturing process as crucial for international success.